Welcome to our dedicated page for TC BIOPHARM HOLDINGS PLC SEC filings (Ticker: TCBWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TC BIOPHARM HOLDINGS PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TC BIOPHARM HOLDINGS PLC's regulatory disclosures and financial reporting.
TC BioPharm (Holdings) plc reports that its directors have resolved to appoint Ben Cairns and Michael Magnay of Alvarez and Marsal Europe LLP as interim liquidators of the company. Addleshaw Goddard LLP has been instructed to file the required court documentation and complete the steps needed to effect the directors’ appointment of these liquidators. The company also plans to file a Form 15 with the U.S. Securities and Exchange Commission to deregister its American Depositary Shares under the Securities Exchange Act of 1934, which will immediately suspend its obligation to file periodic reports once the Form 15 is submitted.